Pom Wonderful LLC v. Federal Trade Commission

894 F. Supp. 2d 40, 2012 WL 4475698, 2012 U.S. Dist. LEXIS 141035
CourtDistrict Court, District of Columbia
DecidedSeptember 30, 2012
DocketCivil Action No. 2010-1539
StatusPublished
Cited by5 cases

This text of 894 F. Supp. 2d 40 (Pom Wonderful LLC v. Federal Trade Commission) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pom Wonderful LLC v. Federal Trade Commission, 894 F. Supp. 2d 40, 2012 WL 4475698, 2012 U.S. Dist. LEXIS 141035 (D.D.C. 2012).

Opinion

MEMORANDUM OPINION

RICHARD W. ROBERTS, District Judge.

Plaintiff POM Wonderful LLC (“POM”), the largest processor and distributor of pomegranate products in the United States, brings an action against the Federal Trade Commission (“FTC”) under the Declaratory Judgment Act, 28 U.S.C. § 2201, seeking a declaratory judgment that the FTC’s allegedly new rule governing disease claims in food advertising exceeds the FTC’s statutory authority, violates POM’s rights under the First and Fifth Amendments of the U.S. Constitution, violates the rulemaking procedures of the FTC and the Administrative Procedure Act (“APA”), and is arbitrary and capricious. The FTC has moved under Federal Rules of Civil Procedure 12(b)(1) and 12(b)(6) to dismiss the complaint, arguing that the case is moot, POM lacks standing to bring a declaratory judgment action, POM is attempting to preclude an enforcement action, and POM fails to state a claim upon which relief can be granted. The FTC further argues that the court should decline to exercise jurisdiction to *42 hear this declaratory judgment action. Because circumstances weigh in favor of the court declining to exercise its discretionary jurisdiction- under the Declaratory Judgment Act, the case will be dismissed.

BACKGROUND

In July 2010, the FTC entered written agreements with two companies whose advertisements overstated their products’ effect on disease prevention, mitigation, and treatment. See Stipulated Final J. and Order for Permanent Inj. and Other Equitable Relief, FTC v. Iovate Health Scis. USA, Inc., et al. (“Iovate”), No. 10-cv-587 (W.D.N.Y. July 29, 2010); Agreement Containing Consent Order, In the Matter of Nestlé Healthcare Nutrition, Inc. (“Nestlé”), No. 092-3087, 2010 WL 2811203 (F.T.C. July 14, 2010). Both agreements required the companies to root their future health claims in “competent and reliable scientific evidence ... consisting] of at least two adequate and well-controlled human clinical studies of the [product.]” See Iovate at 7; Nestlé at 4. (See also Compl. ¶¶ 6, 28.) The Nestlé agreement also provided that all disease-based representations be pre-approved by the Food and Drug Administration (“FDA”). Nestlé at 3. (See also Compl. ¶ 27.)

According to POM, these new standards departed from “over twenty ... years of FTC food advertising rules and regulations[.]” (Compl. ¶¶ 5, 25; see also id. ¶ 28.) POM alleged that the FTC had never before “requir[ed] prior FDA approval” irrespective of whether the claims “are true or supported by competent, reliable scientific evidence!.]” (Id. ¶ 25(2).) Neither had the FTC earlier implemented a heightened standard for scientific studies. (Id. ¶ 25(1).) Rather than codifying the new requirements in formal regulations, the FTC allegedly expressed its intention to “universally apply[ ]” them against the food and dietary supplement industry as an enforcement mechanism for deceptive advertising. (Compl. ¶¶ 5, 23-24.) POM alleges that the requirements do not merely “interpret! ] ... present standards or rules.” (Id. ¶ 25(1).) Instead, they “constitute a final agency action within the meaning of’ the APA. (Id. ¶¶ 35, 42, 48, 54.)

POM alleges that by adopting these new rules, the FTC violated statutory and constitutional law. Thus, POM seeks declaratory judgment that the FTC exceeded its statutory authority under Sections 5 1 and 12 2 of the FTC Act by encroaching upon the FDA’s authority, see 15 U.S.C. §§ 45, 52, violated the First and Fifth Amendments of the United States Constitution by chilling free speech without due process, violated the FTC’s rulemaking procedures under Section 18 of the FTC Act, 3 15 *43 U.S.C. § 57a, violated Section 553 of the APA, and adopted a rule that is arbitrary-capricious. 4 (Compl. ¶¶ 8, 12, 29, 51-53.)

On September 27, 2010, approximately two weeks after POM filed the instant case, the FTC filed against POM an administrative complaint alleging that “POM’s practices in promoting pomegranate juice and pills constitute unfair or deceptive acts or practices and false advertising in violation of sections 5(a) and 12 of the FTC Act[.]” (Def.’s Mem. in Supp. of Mot. to Dismiss by FTC (“Def.’s Mem.”) to Dismiss at 5.) 5 In the enforcement action, the FTC is seeking an order that would forbid POM from making certain claims about the health benefits of its products unless “the representation is non-misleading” and the FDA has approved the claims. (Compl. at 21-22, In the Matter of POM Wonderful, et al., No. 9344 (F.T.C. Sept. 27, 2010).) The proposed order would also limit the representations that POM can make about its products and establish substantial future oversight by the FTC. (Id. at 22-25.)

In POM’s answer to the FTC’s complaint, it asserted a number of affirmative defenses. POM argued that “[t]he FTC lacks authority to impose all or part of the relief sought under the FTC Act, the Administrative Procedure Act, and the First and Fifth Amendments of the U.S. Constitution.” (Answer at 7, In the Matter of POM Wonderful, et al., No. 9344 (F.T.C. Oct. 18, 2010).) It also alleged that the FTC has taken a new position in the enforcement action against it “without adequate notice to the public.” (Id.)

The FTC moves to dismiss this action, in part, because this court should exercise its discretion to decline to entertain POM’s declaratory judgment action. (Def.’s Mem. at 10.) Relying on Swish Marketing, Inc. v. FTC, 669 F.Supp.2d 72 (D.D.C.2009), the FTC argues that declaratory relief is not proper because a declaratory judgment would not fully resolve the controversy between the parties, POM’s claims raised in this complaint can be raised in the pending administrative action, and POM’s complaint anticipates defenses. (Id.) POM counters that Swish should be distinguished because the plaintiff in Swish was atypical in that it had “already agreed to stop its allegedly unlawful conduct. Thus, the plaintiffs liability to the defendant as to future damages if any ... [had] now been frozen, so a prompt and speedy adjudication of [the plaintiffs] rights in order to protect it from acting at its peril or avoiding damages in the future [was] unnecessary,” Swish Mktg., 669 F.Supp.2d at 77 (internal citations and quotation marks omitted). (Pl.’s Mem. of P. & A. in Opp’n to Def. FTC’s Mot. to Dismiss at *9.) POM also asserts that its complaint does not attempt *44

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Harris v. Bessent
District of Columbia, 2025
State of New York v. Donald J. Trump
District of Columbia, 2022
Fiberlight, LLC v. National Railroad Passenger Corpration
81 F. Supp. 3d 93 (District of Columbia, 2015)
Morgan Drexen, Inc. v. Consumer Financial Protection Bureau
979 F. Supp. 2d 104 (District of Columbia, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
894 F. Supp. 2d 40, 2012 WL 4475698, 2012 U.S. Dist. LEXIS 141035, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pom-wonderful-llc-v-federal-trade-commission-dcd-2012.